Analysis results showed that 137 main chemical components of ZSS acting on 165 targets including 29 core targets played a significant role in the treatment of CVA, which were concerned with the regulation of inflammatory response and T-cell differentiation, such as IL-17 signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway, T-cell receptor signaling pathway, Th17 cell differentiation, and Th1 and Th2 cell differentiation. The gene discussed is IL17A; the disease is stroke disorder.